SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma informs about press release

15 Dec 2015 Evaluate

Natco Pharma has informed about a Press Release dated December 15, 2015 titled ‘NATCO receives generic Ledipasvir + Sofosbuvir approval for India’.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

896.95 4.00 (0.45%)
24-Jun-2026 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.15
Dr. Reddys Labs. 1331.00
Cipla 1436.00
Zydus Lifesciences 1105.20
Lupin 2373.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: